Corbus Pharmaceuticals — Q3 2026 Earnings Summary

Corbus Pharmaceuticals reported a net loss of $37.8 million for the third quarter of 2026, driven primarily by a $15 million development milestone payment for its sutantatug envedotin program. The company initiated dosing in the registrational TEMPO-1 Phase 3 study for sutantatug envedotin in patients with second-line oropharyngeal cancer and announced positive topline data from the CANYON-1 Phase 1b obesity study of CRB-913. CRB-913 demonstrated a mean weight loss of 5% at a 60 mg daily dose after 12 weeks with a favorable safety profile and no observed plateau. Additionally, Corbus appointed Leonardo Viana Nicacio as Chief Medical Officer and holds $115.3 million in cash and investments, which is projected to fund operations through 2028.